KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.90

Smad7 Antisense Oligonucleotide-Based Therapy in Crohn's Disease: Is it Time to Re-Evaluate?

Giovanni Monteleone, Carmine Stolfi, Irene Marafini, Raja Atreya, Markus F Neurath

Mol Diagn Ther 26(5) 477-481

PMID35841457
PMCIDPMC9411088
DOI10.1007/s40291-022-00606-1
发表日期2022-07-16
入排依据:The record describes a viewpoint/commentary article analyzing the failure of a Phase III trial for mongersen in Crohn's disease (non-oncology). It is not an original report of a primary or secondary efficacy result from a randomized trial with a time-to-event endpoint (OS, PFS, etc.).
摘要

摘要

Abundant preclinical work showed that in Crohn's disease (CD), the defective activity of the immunosuppressive cytokine tumor necrosis factor (TGF)-β1 due to high levels of the intracellular inhibitor Smad7 contributes to amplify the tissue-damaging inflammatory response. Consistently, phase I and II studies documented clinical and endoscopic benefit in active CD patients treated with mongersen, an oral antisense oligonucleotide targeting Smad7. However, a multicenter, randomized, double-blind, placebo-controlled, phase III study was prematurely discontinued as a futility analysis showed that mongersen was not effective in CD patients. The reasons why the phase III study failed despite the fact that previous clinical trials documented the efficacy of the drug remain unknown. The primary objective of this Viewpoint was to provide clues about the factors explaining discrepancies among the clinical trials. We illustrate the recent data indicating that the various batches of mongersen, used during the phase III program, are chemically different, with some of them being unable to downregulate Smad7 expression. Overall, these findings suggest the necessity of new clinical studies to further evaluate the efficacy of chemically homogenous batches of mongersen in patients with inflammatory bowel diseases (IBDs), and, at the same time, they can help understand the failure of other clinical trials with antisense oligonucleotides in IBD (i.e. alicaforsen).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。